PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵: C07D 498/18, C07F 7/18
A61K 31/435 // C07D 498/18
C07D 311:00, 273:00, 221:00

A1

(11) International Publication Number:

WO 94/09010

(43) International Publication Date:

28 April 1994 (28.04.94)

(21) International Application Number:

PCT/EP93/02604

(22) International Filing Date:

24 September 1993 (24.09.93)

(30) Priority data:

9221220.8

9 October 1992 (09.10.92) G

GB |

(71) Applicant (for AT only): SANDOZ-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT M.B.H. [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(71) Applicant (for DE only): SANDOZ-PATENT-GMBH [DE/DE]; Humboldstrasse 3, D-79539 Lörrach (DE).

(71) Applicant (for all designated States except AT DE US): SAN-DOZ LTD. [CH/CH]; Lichtstrasse 35, CH-4002 Basle (CH).

(72) Inventors; and

(75) Inventors/Applicants (for US only): COTTENS, Sylvain [CH/CH]; In den Reben 12, CH-4108 Witterswil (CH). SEDRANI, Richard [LU/CH]; Herrengrabenweg 15, CH-4054 Basle (CH).

(74) Common Representative: SANDOZ LTD.; Patents & Trademarks Div., Lichtstrasse 35, CH-4002 Basle (CH).

(81) Designated States: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, PL, RO, RU, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published

With international search report.

(54) Title: O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNOSUPPRESSANTS

(57) Abstract

Novel O-alkylated derivatives of rapamycin of formula (I), especially 40-O-alkylated derivatives, are found to have pharmaceutical utility, particularly as immunosuppressants.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AT | Acceded | nn. | Page | 440 | NAtata |
|----|--------------------------|-----|------------------------------|-----|--------------------------|
| | Austria | FR | France | MR | Mauritania |
| ΑU | Australia | GA | Gabon | MW | Malawi |
| BB | Barbados | GB | United Kingdom | NE | Niger |
| BE | Belgium | GN | Guinea | NL | Netherlands |
| BF | Burkina Faso | GR | Greece | NO | Norway |
| BG | Bulgaria | HU | Hungary | NZ | New Zealand |
| BJ | Benin | ΙE | Ireland | PL | Poland |
| BR | Brazil | lТ | Italy | PT | Portugal |
| BY | Belarus | JP | Japan | RO | Romania |
| CA | Canada | KP | Democratic People's Republic | RU | Russian Federation |
| CF | Central African Republic | | of Korea | SD | Sudan |
| CG | Congo | KR | Republic of Korea | SE | Sweden |
| CH | Switzerland | KZ | Kazakhstan | SI | Slovenia |
| Cl | Côte d'Ivoire | LI | Liechtenstein | SK | Slovak Republic |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CN | China | LU | Luxembourg | TD | Chad |
| CS | Czechoslovakia | LV | Latvia | TG | Togo |
| CZ | Czech Republic | MC | Monaco | UA | Ukraine |
| DE | Germany | MG | Madagascar | US | United States of America |
| DK | Denmark | ML | Mali | UZ | Uzbekistan |
| ES | Spain | MN | Mongolia | VN | Viet Nam |
| FI | Finland | | • | | |



O-ALKYLATED RAPAMYCIN DERIVATIVES AND THEIR USE, PARTICULARLY AS IMMUNO-SUPPRESSANTS

This invention comprises novel alkylated derivatives of rapamycin having pharmaceutical utility, especially as immunosuppressants.

Rapamycin is a known macrolide antibiotic produced by <u>Streptomyces</u> hygroscopicus, having the structure depicted in Formula A:

See, e.g., McAlpine, J.B., et al., J. Antibiotics (1991) 44: 688; Schreiber, S.L., et al., J. Am. Chem. Soc. (1991) 113: 7433; US Patent No. 3 929 992. Rapamycin is an extremely

potent immunosuppressant and has also been shown to have antitumor and antifungal activity. Its utility as a pharmaceutical, however, is restricted by its very low and variable bioavailability as well as its high toxicity. Moreover, rapamycin is highly insoluble, making it difficult to formulate stable galenic compositions.

It has now surprisingly been discovered that certain novel derivatives of rapamycin (the Novel Compounds) have an improved pharmacologic profile over rapamycin, exhibit greater stability and bioavailability, and allow for greater ease in producing galenic formulations. The Novel Compounds are alkylated derivatives of rapamycin having the structure of Formula I:

wherein



X is (H,H) or O;

Y is (H,OH) or O;

R1 and R2 are independently selected from

H, alkyl, thioalkyl, arylalkyl, hydroxyalkyl, dihydroxyalkyl, hydroxyalkylarylalkyl, alkoxyalkyl, acyloxyalkyl, aminoalkyl, alkylaminoalkyl, alkoxycarbonylaminoalkyl, acylaminoalkyl, arylsulfonamidoalkyl, allyl, dihydroxyalkylallyl, dioxolanylallyl, carbalkoxyalkyl, and $(R^3)_3$ Si where each R^3 is independently selected from H, methyl, ethyl, isopropyl, <u>t</u>-butyl, and phenyl; wherein "alk-" or "alkyl" refers to $C_{1.6}$ alkyl, branched or linear preferably $C_{1.3}$ alkyl, in which the carbon chain may be optionally interrupted by an ether (-O-) linkage; and

R4 is methyl, or R4 and R1 together form C26 alkylene;

provided that R^1 and R^2 are not both H; and provided that where R^1 is $(R^3)_3$ Si or carbalkoxyalkyl, X and Y are not both O.

Preferred Novel Compounds include the following:

- 1. 40-O-Benzyl-rapamycin
- 2. 40-O-(4'-Hydroxymethyl)benzyl-rapamycin
- 3. 40-O-[4'-(1,2-Dihydroxyethyl)]benzyl-rapamycin
- 4. 40-O-Allyl-rapamycin
- 5. 40-O-[3'-(2,2-Dimethyl-1,3-dioxolan-4(S)-yl)-prop-2'-en-1'-yl]-rapamycin
- 6. (2'E, 4'S)-40-O-(4',5'-Dihydroxypent-2'-en-1'-yl)-rapamycin
- 7. 40-O-(2-Hydroxy)ethoxycarbonylmethyl-rapamycin
- 8. 40-O-(2-Hydroxy)ethyl-rapamycin



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

